{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:20:40Z","timestamp":1730434840479,"version":"3.28.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,31]]},"DOI":"10.7759\/cureus.72797","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T01:07:44Z","timestamp":1730423264000},"source":"Crossref","is-referenced-by-count":0,"title":["Cetuximab-Induced Pneumonitis: An Overlooked Complication"],"prefix":"10.7759","author":[{"given":"Oluwatosin","family":"Emehinola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruhma","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunwant","family":"Guron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/JIPO.JIPO_9_18","article-title":"Pneumonitis after precision oncology therapies: a concise review","volume":"1","author":"Jain A","year":"2018","unstructured":"Jain A, Shannon VR, Sheshadri A. Pneumonitis after precision oncology therapies: a concise review. J Immun Precision Oncol. 2018, 1:26-37. 10.4103\/JIPO.JIPO_9_18","journal-title":"J Immun Precision Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-113","article-title":"Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review","volume":"28","author":"Hoag JB","year":"2009","unstructured":"Hoag JB, Azizi A, Doherty TJ, Lu J, Willis RE, Lund ME. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res. 2009, 28:113. 10.1186\/1756-9966-28-113","journal-title":"J Exp Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.2.175","article-title":"Incidence and management of cutaneous toxicities associated with cetuximab","volume":"6","author":"Saif MW","year":"2007","unstructured":"Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007, 6:175-182. 10.1517\/14740338.6.2.175","journal-title":"Expert Opin Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.10.007","article-title":"Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. multi-society task force on colorectal cancer","volume":"162","author":"Patel SG","year":"2022","unstructured":"Patel SG, May FP, Anderson JC, et al.. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. multi-society task force on colorectal cancer. Gastroenterology. 2022, 162:285-299. 10.1053\/j.gastro.2021.10.007","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem E","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E, et al.. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009, 360:1408-1417. 10.1056\/NEJMoa0805019","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S242224","article-title":"Recent advantages on our knowledge of mCRC tumor biology and genetics: a focus on targeted therapy development","volume":"14","author":"Gmeiner WH","year":"2021","unstructured":"Gmeiner WH. Recent advantages on our knowledge of mCRC tumor biology and genetics: a focus on targeted therapy development. Onco Targets Ther. 2021, 14:2121-2130. 10.2147\/OTT.S242224","journal-title":"Onco Targets Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-022-00339-2","article-title":"Treatment pathways and associated costs of metastatic colorectal cancer in Greece","volume":"20","author":"Sougklakos I","year":"2022","unstructured":"Sougklakos I, Athanasiadis E, Boukovinas I, et al.. Treatment pathways and associated costs of metastatic colorectal cancer in Greece. Cost Eff Resour Alloc. 2022, 20:7. 10.1186\/s12962-022-00339-2","journal-title":"Cost Eff Resour Alloc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan TS","year":"2011","unstructured":"Maughan TS, Adams RA, Smith CG, et al.. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011, 377:2103-2114. 10.1016\/S0140-6736(11)60613-2","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz HJ","year":"2006","unstructured":"Lenz HJ, Van Cutsem E, Khambata-Ford S, et al.. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006, 24:4914-4921. 10.1200\/JCO.2006.06.7595","journal-title":"J Clin Oncol"},{"key":"ref10","article-title":"The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck","volume":"6","author":"Mehra R","year":"2008","unstructured":"Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol. 2008, 6:742-750.","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212447973","article-title":"Aseptic meningitis: a rare side effect of cetuximab therapy","volume":"19","author":"Emani MK","year":"2013","unstructured":"Emani MK, Zaiden RA Jr. Aseptic meningitis: a rare side effect of cetuximab therapy. J Oncol Pharm Pract. 2013, 19:178-180. 10.1177\/1078155212447973","journal-title":"J Oncol Pharm Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu128","article-title":"Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry","volume":"44","author":"Satoh T","year":"2014","unstructured":"Satoh T, Gemma A, Kudoh S, et al.. Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry. Jpn J Clin Oncol. 2014, 44:1032-1039. 10.1093\/jjco\/hyu128","journal-title":"Jpn J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/2331205X.2017.1284419","article-title":"Being aware of potentially fatal interstitial lung disease in patients with head and neck cancer treated with concurrent cetuximab and radiotherapy","volume":"4","author":"Mari S","year":"2017","unstructured":"Mari S, Hiroshi N, Toru S, Takafumi N, Hirofumi F. Being aware of potentially fatal interstitial lung disease in patients with head and neck cancer treated with concurrent cetuximab and radiotherapy. Cogent Med. 2017, 4:1. 10.1080\/2331205X.2017.1284419","journal-title":"Cogent Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo K","year":"2013","unstructured":"Kubo K, Azuma A, Kanazawa M, et al.. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013, 51:260-277. 10.1016\/j.resinv.2013.09.001","journal-title":"Respir Investig"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0761-841784804-7","article-title":"Nouvelle classification des pneumopathies interstitielles diffuses [New classification of interstitial lung disease]","volume":"61","author":"Capron F","year":"2005","unstructured":"Capron F. Nouvelle classification des pneumopathies interstitielles diffuses [New classification of interstitial lung disease]. Rev Pneumol Clin. 2005, 61:133-140. 10.1016\/s0761-841784804-7","journal-title":"Rev Pneumol Clin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/304041-cetuximab-induced-pneumonitis-an-overlooked-complication","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T01:07:46Z","timestamp":1730423266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/304041-cetuximab-induced-pneumonitis-an-overlooked-complication"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.72797","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}